As a recognized service provider, Creative Biolabs’ highly skilled team can provide CellRapeutics™ first generation of CARs products to meet your specific needs. Creative Biolabs has built up a unique and unparalleled platform for producing a variety of CARs engineered immune cells, which can greatly help and accelerate your research progress.
Donald R. Shaffer, Penghui Zhou and Stephen Gottschalk. Foreign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains. Med. Sci. 2014, 2(1), 23-36.
The design of the first generation CARs includes a scFv targeting tumor associated antigen (TAA), a space (hinge), a transmembrane region (TM) and an intracellular signaling domain. Clinical trials have shown that the first generation CAR-engrafted T cells are a very feasible concept in the treatment for some cancer patients. The application of CAR-engineered T cells have more advantages than the traditional T cell immunotherapy, which includes major histocompatibility complex (MHC)-independent antigen recognition in treating viral infection as well as cancer. Recent reports show that the first generation CAR modified T cells with anti-CD19 specificity has entered phrase I clinical trial for B cell malignances.
The scFv of the first generation CAR is derived from a monoclonal antibody specific to TAAs which is presented on tumor cell surface in various malignancies. Our seasoned scientists can provide a broad range of highly customized service for scFvs design to meet the growing requirements from our clients. An intracellular signaling domain is derived from the CD3ζ chain of the T cell receptor (TCR) complex, which can activate T cells. In addition to CD3ζ, FcεRIγ can also be used as an intracellular signaling domain.
Creative Biolabs offers you sophisticated strategy and the best-in-class CellRapeutics™ first generation CARs products, which can meet and exceed your original expectations.
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved